发明名称 COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR
摘要 The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1 C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1 C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C- 4C)alkyl, optionally halogenated (1 C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1 C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1 C-4C)alkoxy or optionally halogenated aryl(1 C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1 C-4C)alkyl, or R6 is optionally halogenated (1 C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1 C-4C)alkyl or optionally halogenated (1 C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.
申请公布号 CA2631816(C) 申请公布日期 2014.05.06
申请号 CA20062631816 申请日期 2006.12.18
申请人 N.V. ORGANON;PHARMACOPEIA, INC. 发明人 HAMILTON, NIALL MORTON;GROVE, SIMON JAMES ANTHONY;KICZUN, MICHAEL JOHN;MORPHY, JOHN RICHARD;SHERBORNE, BRAD;LITTLEWOOD, PETER THOMAS ALBERT;BROWN, ANGUS RICHARD;KINGSBURY, CELIA;OHLMEYER, MICHAEL;HO, KOC-KAN;KULTGEN, STEVEN G.
分类号 C07C311/17;A61K31/18;A61K31/341;A61K31/415;A61K31/42;A61K31/44;A61K31/4436;A61K31/4439;A61P25/22;A61P25/24;C07D213/85;C07D231/18;C07D261/10;C07D307/64;C07D333/34;C07D401/12;C07D409/12;C07D413/12 主分类号 C07C311/17
代理机构 代理人
主权项
地址